Dr. Matt Galsky highlights how data from CREST and KEYNOTE trials support expanding immunotherapy use in bladder cancer, particularly in high-risk NMIBC and MIBC. He explains that EV pembrolizumab demonstrates strong, consistent benefits across endpoints, including pathologic response and event-free survival without compromising surgery outcomes. While EV-pembro is often preferred, he notes that patient selection remains critical, especially in variant histologies where alternative chemo-immunotherapy combinations may still be appropriate.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
